Introduction {#Sec1}
============

The increasing availability of fully sequenced genomes is making the high-throughput proteomics research more and more possible. Developments in fractionation approaches coupled to advances in liquid chromatography (LC), mass spectrometry (MS), and bioinformatic tools have made proteomic approaches mature to analyze complex proteomes, such as *Homo sapiens* (Nilsson et al. [@CR70]). In fact, although proteome complexity prevents the quantitative profiling of all proteins expressed in a cell or tissue at a given time, higher sensitivity, accuracy, and resolution of new MS instruments allow routine analysis, reaching limit of detection of attomole and dynamic range of 1e^6^ (Yates et al. [@CR100]).

High-throughput proteomics approaches allow to identify and quantify hundreds of proteins per sample, giving a snapshot of cells or tissues associated with different phenotypes. This wealth of data has driven strategies of investigation based on systems biology approaches, allowing insight into disease, taking into consideration functional relationship among proteins (Gstaiger and Aebersold [@CR37]). In addition, highly specific biomarkers represent also key features for improving methods of diagnosis and prognosis or for monitoring disease progression under appropriate therapeutic approaches (Palmblad et al. [@CR73]; Simpson et al. [@CR88]). In this context, MS has been introduced as a tool for enhancing the current clinical application practices and potentially for targeting the development of personalized medicine (Brambilla et al. [@CR15]).

The ultimate success of MS-based proteomics analysis, both for research and for clinical applications, may be affected by several aspects. Like sample preparation, pre-fractionation methodologies, or instrument setup, data processing procedures represent an important step for obtaining good results and their correct interpretation. Evaluation of thousands of data by hand/eye is time consuming and subjected to biases and missed results. Therefore, to assist researchers during the different stages of analysis and to improve understanding of biological systems, an increasing number of tools and procedures are continually developing, giving rise to a specific bioinformatics area for proteomic applications (Di Silvestre et al. [@CR30]).

In this chapter, we make an overview of the computational trends for processing proteomic data obtained by MS-based proteomics approaches. Based on our experience, we focused primarily on strategies related to multidimensional protein identification technology (MudPIT) approach (Mauri and Scigelova [@CR63]), (Fig. [9.1](#Fig1){ref-type="fig"}). In particular, we have explored methods, algorithms, and procedures used for biomarker discovery, by means of label and label-free methods. In this context, we then introduce the main advances of the targeted proteomics (Lange et al. [@CR52]) by investigating the bioinformatics aspects concerning the identification of proteotypic peptides (Craig et al. [@CR24]; Kuster et al. [@CR51]). In the second part of the chapter, we discuss recent advances regarding clinical proteomics application for discriminating sample, such as diseased and healthy. Finally, since most known mechanisms leading to disease involve multiple molecules, we conclude with a discussion of the integration of proteomic data with network datasets, as a promising framework for identifying subnetwork that underlines the emergence of specific phenotypes.Fig. 9.1Multidimensional protein identification technology represents a fully automated technology that simultaneously allows separation of digested peptides, their sequencing, and identification of the corresponding proteins. Peptides are separated by means of strong ion exchange (*SCX*), using steps of increasing salt concentration, followed by C18 reverse phase (*RP*) chromatography, using an acetonitrile gradient. Finally, eluted peptides are directly analyzed by MS and raw spectra processed by specific algorithms and bioinformatics tools (see Supplemental Information Table [1](#Tab1){ref-type="table"}). In this way, MudPIT permits simultaneous identification of hundreds, or even thousands, of proteins without limits related to pI, MW, or hydrophobicity. This huge amount of data represents a rich source of information, and their content may be exploited for discovery and classification approaches

Biomarker Discovery {#Sec2}
===================

Quantification of proteomic differences between samples at different biological condition, such as healthy and diseased, is a helpful strategy for providing important biological and physiological information concerning disease state (Simpson et al. [@CR88]; Abu-Asab et al. [@CR1]). For this purpose, MS-based approaches are applied for identifying proteins changing their abundance by comparing two or more samples. They consist of different strategies basically belonging to two categories which rely on stable isotope-labeling and label-free methodologies (Domon and Aebersold [@CR31]).

As for labeling approaches, isotopes are introduced in the peptides to create a specific mass tag recognized by MS (Kline and Sussman [@CR50]). Accordingly, quantification is achieved by measuring the ratio of the signal intensities between the unlabeled peptide and its identical counterpart enriched with isotopes (further details on stable isotope-labeling methods are reported in [Supplemental Information](#Sec7){ref-type="sec"}). Absolute measurements of protein concentration may be achieved with spiked synthetic peptides, as in QconCAT (Mirzaei et al. [@CR65]), AQUA (Gerber et al. [@CR36]), SISCAPA (Anderson et al. [@CR3]), VICAT (Lu et al. [@CR56]), and PC-IDMS (Barnidge et al. [@CR10]). Quantification is obtained by adding into the sample a known amount of an isotopically labeled peptide. In this way, the level of the endogenous form of peptide can be calculated. Of course, the identity of the peptide must be known prior to analysis by MS. Sometimes, if the m/z ratio of the spiked standard is the same of other peptides, it may lead to an inaccurate quantification. In this case, the ambiguity of the results may be minimized combining these approaches with the selected reaction monitoring (SRM) (Lange et al. [@CR52]).

Although the approaches by labeling, with or without internal standard, allow a highly reproducible and accurate quantification of proteins, most of them have potential limitations, such as the complexity of sample preparation, the requirement of a large amount of time, the requirement of specific bioinformatics tools, and the high cost. As opposite, a simpler alternative concerns label-free approaches (Zhu et al. [@CR104]). They are basically based on counting of peptides identified by means of tandem mass spectrometry (MS/MS) or by evaluating the signal intensity of peptides. Spectral sampling is directly proportional to the relative abundance of the protein in the mixture and therefore represents an attractive methodology, thanks to their intrinsic simplicity, throughput, and low cost.

For these reasons, researchers are increasingly turning to label-free shotgun proteomics approaches (Zhu et al. [@CR104]). Even if they are less accurate, due to the systematic and nonsystematic variations between the experiments, they represent an attractive alternative for their high-throughput setting that also allows the comparison of an unlimited number of experiments with less time consumed. However, efforts should be made to improve experimentally reproducibility and so consequently the reliability of differentially expressed proteins.

A variety of label-free methodologies for semiquantitative evaluation of proteins have been described in literature by reporting a direct relationship between the protein abundance and the sampling parameters associated with identified proteins and peptides (Florens et al. [@CR33]; Gao et al. [@CR35]; Wang et al. [@CR95]; Bridges et al. [@CR18]). One of the most diffused approaches uses the spectral count (SpC) value (Liu et al. [@CR55]) and is based on the empirical observation that more is the quantity of a protein in a sample and more tandem MS spectra may be collected for its peptides. In this context, the normalized spectral abundance factor (NSAF), or its natural log transformation, has been used for the quantitative evaluation with t-test analysis (Zybailov et al. [@CR105]). Other authors have used the protein abundance index (PAI or emPAI) that is calculated by dividing, for each protein, the number of observed peptides by the number of all possible detectable tryptic peptides (Ishihama et al. [@CR43]), while Zhang and colleagues processed SpC values by means of the statistical G-test as previously described (Zhang et al. [@CR103]).

The need to automate the procedure for identifying biomarkers has driven many research groups to develop algorithms and in-house software for identification, visualization, and quantification of mass spectrometry data. Census (Park et al. [@CR74]) and MSQuant (Mortensen et al. [@CR67]) software allows protein quantification by processing MS and MS/MS spectra and they are compatible with label and label-free analysis as well as with high- and low-resolution MS data. In addition, Protein-Quant Suite (Mann et al. [@CR59]) and ProtQuant (Bridges et al. [@CR18]) software are attractive because they allow processing of data in different file formats, therefore collected by different types of mass spectrometers. This aspect focuses attention on the standardization of mass spectrometric data for their sharing and dissemination. In fact, over the years, MS instrument manufacturers have developed proprietary data formats, making it difficult. However, to address this limitation, several tools, such as Trans-Proteomic Pipeline ([@CR29]), allow the conversion of MS data in standard format, like mzData, mzXML, or mzML (Orchard et al. [@CR71]).

The list of computational tools developed for label-free quantitative analysis, by using LC-MS data, is very long. In addition to Corra (Brusniak et al. [@CR19]) and APEX (Braisted et al. [@CR14]) tools, PatternLab (Carvalho et al. [@CR20]) allows different data normalization strategies, such as Total Signal, log preprocessing (by ln), Z normalization, Maximum Signal, and Row Sigma, for implementing ACFold and nSVM (natural support vector machine) methods to identify protein expression differences.

Based on our experience on proteomic analysis based on MudPIT approach, we developed a simple tool, called MAProMA (Multidimensional Algorithm Protein Map) (Mauri and Dehò [@CR62]). It is based on a label-free quantitative approach based on processing of score/SpC values, by means of Dave and DCI algorithms (see [Supplemental Information](#Sec7){ref-type="sec"}). Its effectiveness has been demonstrated in various studies (Mauri et al. [@CR64]; Regonesi et al. [@CR78]; Bergamini et al. [@CR12]; Simioniuc et al. [@CR87]). In addition, MAProMa allows the comparison of up to 125 protein lists and data visualization in a format more comprehensible to biologists (Fig. [9.2](#Fig2){ref-type="fig"}).Fig. 9.2Virtual 2D MAP tool of MAProMa software allows a rapid evaluation of proteins identified by MudPIT by presenting them in the usual form for biologists (maps). It automatically plots in a virtual 2D map the Mw vs. pI for each protein identified, assigning it a color/shape according to a range of a sampling statistics (score or SpC) derived by SEQUEST data handling. This representation permits to have a rapid visual of the proteins that change comparing two or more conditions. In addition, using DAve and DCI algorithms, MAProMa reports a histogram that shows the differentially expressed proteins, their identifier, and their DAve value

Proteotypic Peptides {#Sec3}
====================

A limitation of shotgun proteomics is due to potential inference problem that may affect protein quantification (Nesvizhskii and Aebersold [@CR68]). In addition, limit of detection "may" exclude the identification of biologically relevant molecules. For identifying, validating, and transferring them to the routine clinical analysis, targeted proteomics or "selected reaction monitoring" (SRM) has been recently developed (Lange et al. [@CR52]; Shipkova et al. [@CR86]; Yang and Lazar [@CR99]). The robustness and the simplicity of its data analysis are ideally suited for detecting and quantifying with high confidence up to 100 proteins per sample. For this purpose, mass spectrometers and bioinformatics tools are set to explore a defined number of proteins of interest, following, for each one, a set of representative peptides with a known *m/z* value. They are fragmented, and the monitoring of a specific daughter fragments allow a combination precursor-product, called "transition," that is highly specific for each amino acid sequence.

These peptides, called proteotypic peptides, describe something typical of a protein. Initially, they were defined as the most observed peptides by the current MS-based proteomics approaches (Craig et al. [@CR24]). Then, other authors added the uniqueness condition for a protein (Kuster et al. [@CR51]), while more recently an empirical definition that defines proteotypic peptide as a peptide observed in more than 50% of all identifications of the corresponding parent protein was appended (Mallick et al. [@CR58]). In other words, these peptides have to be previously identified, with a known MS/MS fragmentation pattern and specific for each targeted protein.

The identification of proteotypic peptides useful for targeted proteomics is based on three different methods: By experimental MS/MS dataBy searching in specific databasesBy using predictive strategies

The first one is based on the selection of peptides by using the adopted definitions. It allows also the investigation of organisms with proteotypic peptide data not stored inside specific data repositories. In this context, several databases have been developed. In particular: Global Proteome Machine Database (Craig et al. [@CR23]) allows users to quickly compare their experimental results with the results previously observed by other scientists. For each dataset, it is possible to view observed spectra for the design of SRM experiments. Query of data may be performed by protein name or Ensembl identifier with the possibility to restrict search to a specific data source, such as eukaryotes, prokaryotes, virus, or precise organism. In addition, further filters may be set by keywords comprising organs, cell location, protein function, or PubMed id.GPM project is linked to X! Software series (Craig and Beavis [@CR22]) and, of course, with X! P3, the algorithm that makes possible the use of their spectra for profiling proteotypic peptide.PeptideAtlas (Desiere [@CR28]) is a publicly accessible source of peptides experimentally identified by tandem mass spectrometry. Raw data, search results, and full builds may be also downloaded. User may browse data, selecting different sources, and few of these need the permission to access. Protein may be searched by different protein identifiers, such as Ensembl and IPI. In addition to general information like GO terms, orthologs, or description, a graphical description indicates the unique peptides found and their occurrence. For each one, it is possible to reach information, like spectra, modification, or genome mapping.PeptideAtlas is linked to Trans-Proteomic Pipeline (Deutsch et al. [@CR29]) that is used for processing data passed to PeptideAtlas and SBEAMS (Marzolf et al. [@CR61]). In particular, data are processed for deriving the probability of a correct identification and therefore for insuring a high-quality database.

Other databases, designed for data warehousing, store MS/MS spectra collected from proteomics experiments. Even if they are not useful to find proteotypic peptides, they may be used in the comparison with own experimental data.

In particular: PRIDE (Martens et al. [@CR60]) stores experiments, identified proteins and peptides, unique peptides, and spectra. In addition to protein (name or various identifiers) and PRIDE experiment identifier, it is possible to browse PRIDE by species, tissue, cell type, GO terms, and disease.Proteome Commons (Hill et al. [@CR40]) is a public proteomics database linked to the Tranche (Falkner and Andrews [@CR32]), a powerful open-source web application designed to store and exchange data. A public access to free, open-source proteomics tools, articles, data, and annotations is provided.Proteomexchange (Hermjakob and Apweiler [@CR39]) is a work package for encouraging the data exchange and dissemination. Its consortium has been set up to provide a single point of submission of MS data concerning to the main existing proteomics repositories (at the moment PRIDE, PeptideAtlas, and Tranche).

Experimental data stored in the described repositories represent a wealthy source of information, useful for bioinformaticians which attempt to design algorithms for predicting peptides most observable using MS. For this purpose, the STEPP software contains an implementation of a trained support vector machine (SVM) (Cristianini and Shawe-Taylor [@CR25]; Vapnik [@CR93]) that uses a simple descriptor space, based on 35 properties of amino acid, to compute a score representing how proteotypic a peptide is by LC-MS (Webb-Robertson [@CR96]). Similarly to STEPP, a predictor was developed, called Peptide Sieve (Mallick et al. [@CR58]), by studying physicochemical properties of more than 600,000 peptides identified by four different proteomic platforms. This predictor has the ability to accurately identify proteotypic peptides from any protein sequence and offer starting points for generating a physical model describing the factors that govern elements of proteomic workflows such as digestion, chromatography, ionization, and fragmentation. Other authors, like Tang et al., used neural networks (Riedmiller and Braun [@CR81]) to develop the DetectabilityPredictor software that uses 175 amino acid properties (Tang et al. [@CR92])**.** In the same way, artificial neural networks were used to predict peptides potentially observable for a given set of experimental, instrumental, and analytical conditions concerning multidimensional protein identification technology datasets (Sanders et al. [@CR83]). Finally, random forest (Breiman [@CR16]) was used to develop enhanced signature peptide (ESP) predictor. It was specifically designed for facilitating the development of targeted MS-based assays for biomarker verification or any application where protein levels need to be measured (Fusaro et al. [@CR34]).

Classification and Clustering Algorithms {#Sec4}
========================================

Clinical proteomics aims to use relevant data for improving disease diagnosis or for monitoring its progression (Palmblad et al. [@CR73]; Brambilla et al. [@CR15]). In this context, biomarkers represent a key aspect to develop methods for classifying samples according to their phenotypes (e.g., healthy-diseased, early-late stage).

In addition, to address the biological questions, technologies for high-throughput proteomics allow long lists of spectra, sequenced peptides, and parent proteins that represent a wealthy source of data for identifying predictive biomarkers. For these purposes, most studies have used spectra, generated by MALDI and SELDI technology, in combination with a wide variety of prediction algorithms. On the contrary, fewer cases have taken into consideration data obtained by LC-MS analysis (see Supplemental Information Table [2](#Tab2){ref-type="table"}). However, results of LC-MS analysis (or by MudPIT) are formatted in an *m  ×  n* matrix, with a structure very reminiscent of the output of microarray genomics experiments (Fig. [9.3](#Fig3){ref-type="fig"}). Hence, the software packages and the tools useful for analyzing genomics data may easily be used for proteomics (Ressom et al. [@CR79]; Dakna et al. [@CR26]).Fig. 9.3Data matrix is obtained aligning features identified by analyzing sample by MudPIT approach. In this context, MAProMa software allows a rapid alignment of up to 125 protein lists. Rows in data matrix represent features (e.g., proteins, peptides, or *m*/*z* values) while columns indicate samples. Each cell of data matrix is represented by a value corresponding to parameter associated with features. In particular, spectral count, Xcorrelation (Xcorr), and signal intensity are used for protein, peptides, and *m*/*z* mass features, respectively

Even if some properties of proteomic datasets are related to the analytical technology used to generate them, procedures for sample classification basically consist of four steps, such as data preprocessing, feature selection, classification, and cross-validation (Ressom et al. [@CR79]; Dakna et al. [@CR26]; Sampson et al. [@CR82]; Barla et al. [@CR9]). The first one aims to achieve reproducible results by minimizing errors due to the experimental-designed methodology. Mass spectral profiles may be influenced by several factors, such as baseline effects, shifts in mass-to-charge ratio, alignment problem, or differences in signal intensities that may be corrected by specific computational procedures (Yu et al. [@CR101]; Arneberg et al. [@CR4]; Pluskal et al. [@CR77]). In the same way, variation of sampling parameters associated with sequenced protein, such as spectral count or score, is adjusted using related strategies of data normalization (e.g., Total Signal, log preprocessing (by ln), Z normalization, Maximum Signal, or Row Sigma) (Carvalho et al. [@CR20]).

Typically, MudPIT analysis generates a number of variables usually bigger than the number of analyzed samples (f  \>\>  s). This complexity represents a key problem of computational proteomics, and most classification methods require the reducing of the dimensionality prior to classification. It is obtained by discarding the irrelevant variables for obtaining a combination of features (f  \<\<  s), highly correlated and with a more informative lower dimensional space that maximizes the quality of the hypothesis learned from these features (Guyon et al. [@CR38]).

Feature selection procedures may be classified in three different approaches based on different processes to rank features: filter, wrapper, and embedded (Levner [@CR53]). A number of techniques have been used for the analysis of proteomic data, and these include methods such as support vector machines (SVM) and artificial neural networks (ANN) as well as approaches like partial least squares (PLS), principal component regression (PCR), and principal component analysis (PCA). A good overview of statistical and machine learning-based feature selection and pattern classification algorithms is reported by Ressom and colleagues (Ressom et al. [@CR79]). Of course, different combinations of them show different sensitivity to noisy data and outliers as well as different susceptibility to the over-fitting problem (Sampson et al. [@CR82]).

A limitation of many machine learning-based classification algorithms is that they are not based on a probabilistic model; therefore, there is no confidence associated with the predictions of new datasets. Inadequate performance could be attributed to different reasons (e.g., insufficient or redundant features, inappropriate model classifier, few or too many model parameters, under- or overtraining, and code error, as well as presence of highly nonlinear relationships, noise, and systematic bias). Thus, with the purpose of testing the adequacy/inadequacy of a classifier, after learning is completed, its performances are evaluated through validation set, previously unseen. For this purpose, various methods, such as *k*-fold cross-validation, bootstrapping, and holdout methods, have been used (Ressom et al. [@CR79]). The most common performance measures to evaluate the performances of classifiers are a confusion matrix and a receiver operating characteristic (ROC) curve. The first one shows information about actual and predicted classifications of a classifier and assesses its performances using standard indices, such as sensitivity, specificity, PPV, NPV, and accuracy values (see [Supplemental Information](#Sec7){ref-type="sec"}). On the other hand, ROC is a plot of the sensitivity of a classifier against 1-specificity for multiple decision thresholds.

From Proteomics to Systems Biology {#Sec5}
==================================

Proteomics is a holistic science that refers to the investigation of the entire systems. Before the advent of -omics technologies, reductionism has dominated the biological research for over a century by investigating individual cellular components. Despite its enormous success, it is more and more evident that most molecular functions occur from a concerted action of multiple molecules, and their investigation implies the examination of an ensemble of elements (Barabási and Oltvai [@CR8]). In fact, biomolecular interactions play a role in the majority of cellular processes that are regulated connecting numerous constituents, such as DNA, RNA, proteins, and small molecules.

Data abstraction in pathways or networks is the natural result of the desire to rationalize knowledge of complex systems. More recently, their use has changed from purely illustrative to an analytic purpose. In fact, even if it is purely virtual and not related to any intrinsic structure in the cell or organism, understanding how, where, and when single components interact is fundamental to facilitate the investigation of experimental data by taking into consideration the functional relationship among molecules.

A major challenge for biologists and bioinformaticians is to gain tools, procedures, and skills for integrating data into accurate models that can be used to generate hypotheses for testing. This objective is partially the result of the confluence in systems biology of advances in computer science and -omics technologies. In this context, systems biology approaches have evolved in different strategies basically belonging to two categories, such as computational systems biology, which uses modeling and simulation tools (Barrett et al. [@CR11]; [@CR49]), and data-derived systems biology, which relies on "-omics" datasets (Rho et al. [@CR80]; Li et al. [@CR54]; Jianu et al. [@CR45]; Pflieger et al. [@CR75]).

For deciphering mechanisms of complex and multifactorial diseases, such as those concerning heart failure, recent studies have coupled proteomic and systems biology approaches (Wheelock et al. [@CR97]; Isserlin et al. [@CR44]; Arrell et al. [@CR5]). From a standpoint of the data visualization, the possibility to map protein expression onto pathway or network reveals how they are modulated under different conditions, such as healthy and disease states (Gstaiger and Aebersold [@CR37]; Sodek et al. [@CR89]). About that, an unbiased procedure to identify subnetworks which change consistently between different states involves three key steps: The execution of high-throughput proteomic experimentsThe identification of candidate biomarkers by label or label-free methodsThe integration of data into network model to identify clusters of proteins with under, over, and normal expression

In addition, subnetwork selected using experimental data may be analyzed by computing network centrality parameters (Scardoni et al. [@CR84]) for identifying proteins with a relevant biological and topological significance (Fig. [9.4](#Fig4){ref-type="fig"}). However, some limitations concerning this kind of approaches could be represented by measurements that cover only a small fraction of the network or by organisms with a limited dataset of cataloged protein sequences and interactions.Fig. 9.4By means of Cytoscape software and its plugins, proteins and biomarkers identified by MudPIT are integrated in protein network for identifying pathways or subnetworks that underline the emergence of specific biological states. In addition, networks identified by experimental data may be analyzed by plugins, such as CentiScape, for calculating centrality parameters that indicate nodes with relevant biological and topological significance

To date, in order to visualize and analyze biological networks, a wide set of bioinformatic tools are available (Suderman and Hallett [@CR91]) and include well-known examples, such as Cytoscape (Shannon et al. [@CR85]), VisANT (Hu et al. [@CR41]), Pathway Studio (Nikitin et al. [@CR69]), PATIKA (Demir et al. [@CR27]), Osprey (Breitkreutz et al. [@CR17]), and ProViz (Iragne et al. [@CR42]). Among these, Cytoscape is a Java application whose source code is released under the Lesser General Public License (LGPL). It is probably the most famous open-source software platform for visualizing network datasets and biological pathways and for integrating them with annotations or gene and protein expression profiles. Its core distribution provides a basic set of features. However, additional features are available as plugins, thanks to a big community of developers which uses the Cytoscape open API based on Java technology.

Most of the plugins are freely available and concern tasks like the importing and the visualizing of networks from various data formats, the generating of networks from literature searches, and the analysis or the filtering of them by selecting subsets of nodes and/or interactions in relation with topological parameters, GO annotation, or expression levels. In particular, for analyzing large set of proteomics data, we suggest some plugins, such as: CentiScape (Scardoni et al. [@CR84]) that computes specific centrality parameters describing the network topologyMCODE (Bader and Hogue [@CR7]) that finds clusters or highly interconnected regionsBiNGO (Maere et al. [@CR57]) that determines the Gene Ontology (GO) categories statistically overrepresented in a set of genes or a subgraph of a biological networkBioNetBuilder (Avila-Campillo et al. [@CR6]) that offers a user-friendly interface to create biological networks integrated from several databases such as BIND (Alfarano et al. [@CR2]), BioGRID (Stark et al. [@CR90]), DIP (Xenarios et al. [@CR98]), HPRD (Mishra et al. [@CR66]), KEGG ([@CR47]), IntAct (Kerrien et al. [@CR48]), MINT (Zanzoni et al. [@CR102]), MPPI (Pagel et al. [@CR72]), and Prolinks (Bowers et al. [@CR13]) as well as interolog networks derived from these sources for all species represented in NCBI HomoloGene

Other important repositories for protein-protein interaction are STRING (von Mering et al. [@CR94]), Reactome (Joshi-Tope et al. [@CR46]), Pathway Commons (Cerami et al. [@CR21]), and WikiPathways (Pico et al. [@CR76]). However, an exhaustive overview of existing databases is available through the Pathguide website (<http://www.pathguide.org/>), a useful web resource where about 300 biological pathways and interaction database are described.

Conclusion {#Sec6}
==========

In the last few years, developments in MS instrumentation have increased both the number of identified proteins, reaching hundreds to thousands in a single experiment, and the confidence of such identifications. Thanks to this relevant amount of data, researchers are characterizing the discovery processes by integrating large set of experimental data into models used to generate hypothesis for testing. For this purpose, systems biology approaches provide a powerful strategy for linking biomarker expression with biological processes that can be segmented and linked to disease presentation. Mass spectrometry-based proteomics is emerging also as a powerful approach suitable to face clinical questions. Even if it is an area of still unrealized potential, clinical proteomics offers the promise of diagnosis, prognosis, and therapeutic follow-up of human diseases. However, given the current status of measurement reproducibility and lack of standardization, further comparative investigations are of great importance.

As widely emerged by this chapter, both for basic or clinical research, bioinformatics and statistical tools have a primary importance to support the discovery processes at various levels of sophistication, or for improving the performances of the technologies themselves. In particular, the relevant amount of data produced by the high-throughput proteomics technologies require powerful informatics supports for their organization and interpretation. In this context, several topics concerning data storage, their processing, their visualization, and their interpretation have been faced. However, the need of standards is considered fundamental, and some projects for sharing experimental data between research groups have been launched (e.g., MIAPE, CDISC, and HL7). These should increase meta-analysis, by using raw data from different centers, for helping the development that was grossly underestimated in the initial studies. In addition, as a proteomics community, we believe proteomics methodologies mature for tackling future challenges in clinical proteomics. However, the production of valuable data should rise in step with cooperation with medically focused groups.

Supplemental Information {#Sec7}
========================

Introduction {#Sec8}
------------

Table 1Bioinformatics platforms for processing proteomics dataNameDescriptionReferences**Corra**Frameworks for LC-MS analysis[@CR110])**ATAQS**Pipeline implemented for SRMBrusniak et al. ([@CR111])**Central Proteomics Facilities Pipeline**Pipeline for the analysis of MS/MS proteomic dataTrudgian et al. ([@CR162])**SASHIMI**Suite of tools for MS/MS proteomics[@CR11])**MS Data Miner**A web-based software that accepts data from Mascot or other softwareDyrlund et al. ([@CR118])**Katsura**Overlays -omics empirical data onto metabolic pathways[@CR129])**ProteoWizard**Set of libraries and tools to perform proteomics data analysisKessner et al. ([@CR130])**ProteoConnections**Web-based set of tools using for analyzing proteomic dataCourcelles et al. ([@CR114])**Chipster**A Java Web Start framework that organizes workflows for -omics dataKallio et al. ([@CR128])**Multiplierz**A scriptable framework that access to manufacturer data filesParikh et al. ([@CR148])**Proteomatic**A framework that permits to create concatenate scripts in pipelineSpecht et al. ([@CR157])**DAnTE/Inferno**Software to perform statistical analysis on proteomics dataPolpitiya et al. ([@CR150])

Biomarker Discovery (Stable Isotope Labeling) {#Sec9}
---------------------------------------------

As for labeling approaches, the stable isotopes may be introduced in the peptide using different methods based on the metabolic, chemical, or enzymatic incorporation (Ong and Mann [@CR146]). Metabolic labeling was described for marking protein of yeast by means of ^15^N-enriched cell culture medium (Oda et al. [@CR145]). Since the number of labeled nitrogen atoms may vary from peptide to peptide, stable isotope labeling by amino acids in cell culture (SILAC) approach (Ong et al. [@CR147]) was then introduced. In this case, culture medium contains ^13^C~6~-Lys and ^13^C~6~ and ^15^N~4~-Arg, ensuring at least one labeled amino acid of tryptic cleavage products. In addition, samples treated with different isotopes may be combined prior to sample preparation minimizing the potential errors introduced by their handling. However, a low cellular growth in adapted media may represent a potential drawback.

Methods which allow labeling by chemical or enzymatic incorporation overcome some limitations associated with metabolic labeling. They include isotope-coded affinity tags (ICAT), where free cysteine residues are tagged by a reagent containing eight or zero deuterium atoms (Gygi et al. [@CR124]). Tags are linked to the biotin which may be exploited for enriching the labeled peptides using affinity purification prior to MS analysis. Although this strategy reduces the complexity of the peptide mixture, proteins that do not contain cysteine are excluded from the analysis. For this reason, other approaches use reactive residues that occur more frequently in proteins. At this class belong the isobaric tags for relative and absolute quantitation (iTRAQ) (Ross et al. [@CR153]), the tandem mass tags (TMT) (Thompson et al. [@CR160]), and the isotope-coded protein label (ICPL) (Schmidt et al. [@CR154]). In particular, iTRAQ approach is widely used and it is based on the covalent labeling of the N-terminus and side chain amines of peptides. Multiplexing tagging allows the analysis of up to 8 samples per experiment (Choe et al. [@CR113]). In fact, samples differently tagged are pooled and usually fractionated by LC and analyzed by MS/MS. However, problem of co-elution of peptides with similar mass could interfere with the quantification. Finally, as for enzymatic tagging of peptides, recently trypsin-catalyzed ^18^O labeling has grown in popularity due to its simplicity, its cost, and its ability to universally label peptides. Both C-terminal carboxyl group atoms of tryptic peptides can be enzymatically exchanged with ^18^O providing a labeled peptide with a 4-Da mass shift from the ^16^O-labeled sample (Qian et al. [@CR151]).

Biomarker Discovery (DAve and DCI Algorithms) {#Sec10}
---------------------------------------------

A direct correlation between the SEQUEST-based score value and the relative abundance of the identified proteins has been previously demonstrated ([@CR143]; [@CR152]). Based on this finding, protein profiles of healthy and diseased samples are semiquantitatively compared using a label-free proteomic approach based on DAve (differential average) and DCI (differential confidence index) algorithms of MAProMA software ([@CR142]).

In particular, DAve, which evaluates changes in protein expression, is defined as $$\documentclass[12pt]{minimal}
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\end{document}$$ while DCI, which describes the confidence of differential expression, is defined as $$\documentclass[12pt]{minimal}
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\end{document}$$ where *X* and *Y* represent the SEQUEST-based score or SpC values of a given protein in two compared samples.

Conventionally, signs (+/−) of DAve and DCI indicate if proteins are up-regulated in the first or in the second sample, respectively. A value of DAve \>0.4 (or ≤ −0.4) corresponds to SCORE ratio ≥1.5. Coupled to a threshold value ≥400 (or ≤ −400) for DCI, it allows, with a good reliability, to identify differentially expressed ([@CR143]; [@CR155]; [@CR109]) proteins. However, DAve and DCI threshold values may be decreased when calculated, considering mean SCORE values derived from replicate analyses (DAve ≥0.2 or \< −0.2 and DCI ≥200 and ≤ −200). On the contrary, when a single analysis per sample/condition is available, a better reliability of the differentially expressed proteins may be assured increasing the threshold values (DAve ≥0.8 or \< −0.8 and DCI ≥800 and ≤ −800).
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Table 2Classification studies published in the last few yearsSampleReferencesTechnologyDataAlgorithmBiological condition**Urine**Dawson et al. ([@CR115])MALDI**Proteins/peptidesSVM**Ischemic stroke**Serum**Timms et al. ([@CR161])MALDI**----**Ovarian cancer**Virus**Wong et al. ([@CR166])MALDI**SpectraBayes classifiers**Influenza viruses**Tissues**Le Faouder et al. ([@CR137])MALDI-IMS**Protein peaksSVM**Carcinoma**Tissues**M'Koma et al. ([@CR141])MALDI-IMS**Protein Peaksk-nearest-neighbor**Colitis**Tissues**Djidja et al. ([@CR117])MALDI-IMS**Proteins/peptidesPCA-DA**Tumor**Acinetobacter spp.**Alvarez-Buylla et al. ([@CR107])MALDI**----**Acinetobacter spp.**Serum**Fan et al. ([@CR120])MALDI**Raw dataSVM**Breast cancer**Plasma**Fassbender et al. ([@CR121])MALDI**--SVM**Endometriosis**Cerebrospinal fluid**Ishigami et al. ([@CR126])MALDI**SpectraSVM-PCA**Parkinson**Cerebrospinal fluid**Komori et al. ([@CR132])MALDI**SpectraSVM-PCA**Multiple sclerosis disorder**Pollen**Krause et al. ([@CR133])MALDI**Spectra--**Pollen**Tissue**Meding et al. ([@CR144])MALDI**SpectraSVM** **--RF**Tumor**Serum**Pecks et al. ([@CR149])MALDI**--**Preeclampsia**Bronchoal-veolar fluid**Frenzel et al. ([@CR122])MALDI**Protein peaksSVM**ALI/ARDS**Urine**Gao et al. ([@CR123])MALDI**Protein peaksSVM**--**Serum**Han ([@CR125])MALDI**Spectra profileSVM**Hepatitis B**Tissue**Waloszczyk et al.([@CR164])MALDI**Protein peaks--**Lung cancer**Urine**Balog et al. ([@CR108])MALDI**PeptideSVM**Schistosoma mansoni infection**Tissue**[@CR131])MALDI**SpectraSVM-PCA**Gastric cancer**Bacterial suspensions**Lasch et al. ([@CR135])MALDI**SpectraANN**Yersinia**Tissue**Liao et al. ([@CR138])MALDI**Spectra*k*** **NN**Colorectal cancer**Serum**Camaggi et al. ([@CR112])MALDI**--RF**Hepato carcinoma**Plasma**Lin et al.([@CR139])SELDI**Protein peaksPCA**Lung adenocarcinoma**Serum**Van Gorp et al. ([@CR163])SELDI**Protein peaksLS-SVM**Lymph node status in cerebral cancer**Serum**Zhu et al. ([@CR167])SELDI**--SVM**Pancreatic cancer**Endometrial samples**Kyama et al. ([@CR134])SELDI**Protein peaksSVM**Endometriosis**Serum**Fan et al. ([@CR119])SELDI**Protein peaksSVM**Breast cancer**Serum**Liu et al. ([@CR140])SELDI**SpectraDecision tree**Tuberculosis**Serum**Tang et al. ([@CR159])SELDI**SpectraKernel PLS models**Ovarian cancer**Tissues**Wang et al. ([@CR165])SELDI**SpectraANN**Endometriosis**Serum**Song et al. ([@CR156])SELDI and ELISA**Protein peaksSVM**Biliary atresia**Serum**Ahn et al. ([@CR106])Multiplex array--**--**Gastric adenocarcinoma**Plasma**Izbicka et al. ([@CR127])Multiplex immunoassays**SVM**Lung cancer**Tissue**Lazova et al. ([@CR136])IMS**Spectra--**Spitzoid malignant melanoma**Serum**Sui et al.([@CR158])--**--Genetic algorithm**Urinemia*SVM* support virtual machine, *ANN* artificial neural network, *PCA* principal component analysis, *DA* discriminant analysis, *RF* random forest, *PLS* partial least square
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A confusion matrix presents information about actual and predicted classifications made by a classifier. It assesses the classification performance of the classifier. TP, TN, FP, and FN indicate the number of true-positive, true-negative, false-positive, and false-negative samples, respectively. A false positive is when the outcome is incorrectly classified as positive. A false negative is when the outcome is incorrectly classified as negative. True positives and true negatives represent correct classifications. In particular: *Sensitivity*  =  TP/(TP  +  FN)*Specificity*  =  TN/(TN  +  FP)*Positive predictive value*  =  TP/(TP  +  FP)*Negative predictive value*  =  TN/(TN  +  FN)*Overall classification accuracy*  =  (TP  +  TN)/(TP  +  TN  +  FP  +  FN)
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